https://www.selleckchem.com/pr....oducts/terfenadine.h
The NCCN guidelines compliance rate of treatment plans improved from 80% to 94% (p0.001) following MDC discussion. 123 of 300 (41%) patients had treatment plan changes recommended by the MDC. Our results suggest that lung cancer patients have a survival benefit from MDC discussion compared to controls. Patients with advanced disease (stages III and IV) benefited the most. Further research is necessary to understand the precise mechanisms that drive these results. Our results suggest that lung cancer patients have a survival bene